CN104873535A - Anti-adhering liquid of polylactic acid-hydroxyacetic acid copolymer and preparation method thereof - Google Patents

Anti-adhering liquid of polylactic acid-hydroxyacetic acid copolymer and preparation method thereof Download PDF

Info

Publication number
CN104873535A
CN104873535A CN201510249690.9A CN201510249690A CN104873535A CN 104873535 A CN104873535 A CN 104873535A CN 201510249690 A CN201510249690 A CN 201510249690A CN 104873535 A CN104873535 A CN 104873535A
Authority
CN
China
Prior art keywords
glycolide
lactide
poly
polylactic acid
adhering liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510249690.9A
Other languages
Chinese (zh)
Inventor
邱志荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Xun Lang Bioisystech Co Ltd
Original Assignee
Xiamen Xun Lang Bioisystech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen Xun Lang Bioisystech Co Ltd filed Critical Xiamen Xun Lang Bioisystech Co Ltd
Priority to CN201510249690.9A priority Critical patent/CN104873535A/en
Publication of CN104873535A publication Critical patent/CN104873535A/en
Pending legal-status Critical Current

Links

Abstract

The invention relates to anti-adhering liquid of a polylactic acid-hydroxyacetic acid copolymer and a preparation method thereof, relating to medical postoperative anti-adhering liquid; the anti-adhering liquid of the polylactic acid-hydroxyacetic acid copolymer is composed of the polylactic acid-hydroxyacetic acid copolymer and ethyl acetate according to the mass ratio of 1:(1-15); the polylactic acid-hydroxyacetic acid copolymer is composed of polylactic acid and hydroxyacetic acid according to the mass ratio of 1:(0.2-5); the average molecular weight of the polylactic acid-hydroxyacetic acid copolymer is 5000-200000; the anti-adhering liquid of the polylactic acid-hydroxyacetic acid copolymer is prepared by adding ethyl acetate into the polylactic acid-hydroxyacetic acid copolymer and then mixing; when a surgical wound is contacted with the anti-adhering liquid of the polylactic acid-hydroxyacetic acid copolymer, the anti-adhering liquid is rapidly cured to form a thinner membranoid substance stuck on the surgical wound; by utilizing the physical barrier, the tissue wound is prevented from being contacted and adhered; and the anti-adhering liquid disclosed by the invention is free from toxicity and irritation, good in biocompatibility and simple in preparation method.

Description

A kind of Poly(D,L-lactide-co-glycolide antiblocking liquor and preparation method thereof
Technical field
The present invention relates to medical post-operation adhesion preventing liquid, especially relate to a kind of Poly(D,L-lactide-co-glycolide (poly (lactic-co-glycolic acid), PLGA) antiblocking liquor and preparation method thereof.
Background technology
Post-operation adhesion preventing be have history of operation since domestic and international one of still unsolved important topic, the whole nation has nearly various types of operation cases of ten million every year, and nearly all operation all relates to anti and local anti-inflammatory problem between tissue.For preventing tissue adhesion, medical worker carries out unremitting effort always for many years.By early stage surgery once being used the not degradation product implant into body or use the methods such as abdominal cavity built-in silicone oil, medium molecular dextran and streptokinase to prevent adhesion such as foil, mineral oil, silk, rubber, politef, to the nineties in 20th century, the degradation materials such as hyaluronic acid sodium gel, chitin (chitin, chitin) and PLGA film, obtain the license of FDA, obtain clinically using comparatively widely.Polylactic acid membrane and gel products are in wide clinical application in recent years, poly-lactic acid products has the advantage such as good biocompatibility, Absorbable rod, but its solubility is limited, can only be dissolved in several limited chemical reagent having certain toxicity, need in the preparation to use some virose chemical reagent, product has certain remaining.Therefore, market demand exploitation has the absorbability antiblocking liquor of extensive anti effect, thus effectively reduces postoperative complication, improve operative effect, reduce patient's misery, reduce medical expense, and reduce the use of toxic reagent as far as possible, ensure the more safe and effective of product.
In recent years, polymer research achieves gratifying achievement, and PLGA is one of Biodegradable material of current most study.Poly(D,L-lactide-co-glycolide (poly (lactic-co-glycolic acid), PLGA) be polymerized at random by two kinds of monomer-polylactic acid and hydroxyacetic acid, it is a kind of degradable functional polymer organic compound, there is the performance of good biocompatibility, nontoxic, good encystation and film forming, be widely used in pharmacy, medical engineering material and modernization industrial circle.At U.S. PLGA by FDA certification, formally included into American Pharmacopeia as pharmaceutic adjuvant.Pure polylactic acid or glycolic acid polymer compare indissoluble, with it unlike, PLGA presents dissolubility more widely, and it can be dissolved in the middle of more more general solvents.The material of the preparation such as medical operation suture thread and injection microcapsule, microsphere, implants is used as, as the carrier material, bone support, repair materials etc. of medicine, hormone, vaccine and Gene Handling delivery systme through U.S. FDA approval.
Chinese patent CN100493519 discloses a kind of surgical operation antiblocking liquor and preparation method thereof, this antiblocking liquor is made up of the daltonian carboxymethyl chitosan of molecular weight 20 ~ 300,000 of 1 part of weight and the water for injection of 30 ~ 100 parts of weight, and its dynamic viscosity is 100 ~ 800 centipoises.Preparation method comprises except the carboxymethyl-modification of foreign protein pyrogen, chitin in raw material, refining carboxymethyl chitosan, preparation antiblocking liquor and preparation thereof.This antiblocking liquor has excellent biological barrier performance and histocompatibility, is applied to and organizes wound surface, prevents postoperative tissue adhesion, and in human body, intermediate supersession and final metabolite are the metabolites of human normal, is easy to human body and absorbs, avirulence and zest.
Chinese patent CN103263434B discloses a kind of wound washing, antiblocking liquor and its preparation method and application, its composition and weight proportion are: 0.1%-5% sodium carboxymethyl cellulose, 0.1%-10% brown alga oligose, 0.1%-5% hetastarch, 0.1%-5% Polyethylene Glycol, 0.1%-0.9% sodium chloride, all the other are water for injection.Preparation method, is by the mode stirred or be cross-linked, sodium carboxymethyl cellulose, hetastarch are mixed with brown alga oligose, Polyethylene Glycol, sodium chloride and injection water, makes membranoid substance or liquid.This invention has hemostasis, antibacterial, anti, promoting healing several functions simultaneously.
Summary of the invention
The object of the present invention is to provide to be coated on and organize wound surface, meeting water can rapid film formation, a kind of Poly(D,L-lactide-co-glycolide antiblocking liquor preventing postoperative tissue adhesion and preparation method thereof.
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate=1: (1 ~ 15); Described Poly(D,L-lactide-co-glycolide in mass ratio consist of polylactic acid: hydroxyacetic acid=1: (0.2 ~ 5), the mean molecule quantity of described Poly(D,L-lactide-co-glycolide is 0.5 ~ 200,000.
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate can be 1: (1 ~ 3.5);
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate can be 1: (3.5 ~ 7);
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate can be 1: (7 ~ 11);
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate can be 1: (11 ~ 15).
The preparation method of described Poly(D,L-lactide-co-glycolide antiblocking liquor is as follows:
Ethyl acetate is added in Poly(D,L-lactide-co-glycolide, after mixing, namely obtain Poly(D,L-lactide-co-glycolide antiblocking liquor.
Described Poly(D,L-lactide-co-glycolide antiblocking liquor is in use spread evenly across surgical wound surface by doctor, when surgical wound surface contacts with Poly(D,L-lactide-co-glycolide antiblocking liquor, Poly(D,L-lactide-co-glycolide antiblocking liquor rapid solidification becomes very thin membranoid substance, be attached to surgical wound surface, utilize its physical barriers, play the effect preventing from organizing wound surface contact and adhesion.Because the end product of polylactic acid degraded is CO 2and water, intermediate product lactic acid, ethanol is also the homergy product in body, therefore nontoxic, the nonirritant of Poly(D,L-lactide-co-glycolide antiblocking liquor have good biocompatibility.Poly(D,L-lactide-co-glycolide antiblocking liquor is compared with the products such as existing biological Antiadhesive film, Hyaluronat gel, except there is PLGA self character, also have and easily attach that tissue surface, not receptor site change impact, hydrolyzable absorbs, non-toxic substance is left over and the easy advantage such as use, in field of medicaments, application prospect is very wide.
In addition, the preparation method of Poly(D,L-lactide-co-glycolide antiblocking liquor is simple.
Detailed description of the invention
Embodiment 1
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate can be 1: (1 ~ 3.5); Described Poly(D,L-lactide-co-glycolide in mass ratio consist of polylactic acid: hydroxyacetic acid=1: 0.2, the mean molecule quantity of described Poly(D,L-lactide-co-glycolide is 0.5 ten thousand.
Preparation method: ethyl acetate is added and to stir among PLGA and get final product.
Embodiment 2
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate can be 1: (3.5 ~ 7); Described Poly(D,L-lactide-co-glycolide in mass ratio consist of polylactic acid: hydroxyacetic acid=1: 1, the mean molecule quantity of described Poly(D,L-lactide-co-glycolide is 50,000.
Preparation method: with embodiment 1.
Embodiment 3
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate can be 1: (7 ~ 11); Described Poly(D,L-lactide-co-glycolide in mass ratio consist of polylactic acid: hydroxyacetic acid=1: 3, the mean molecule quantity of described Poly(D,L-lactide-co-glycolide is 100,000.
Preparation method: with embodiment 1.
Embodiment 4
Described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate can be 1: (11 ~ 15).Described Poly(D,L-lactide-co-glycolide in mass ratio consist of polylactic acid: hydroxyacetic acid=1: 5, the mean molecule quantity of described Poly(D,L-lactide-co-glycolide is 200,000.
Preparation method: with embodiment 1.
In above-described embodiment, the degradation speed of PLGA is relevant with degree of crystallinity with its molecular weight, and molecular weight is larger, and degree of crystallinity is higher, and degradation speed is slower, and therefore the present invention selects molecular weight and the lower PLGA of degree of crystallinity to make adherence preventing material; The filming performance of PLGA is also relevant with its molecular weight, and experimentation proves that antiblocking liquor filming performance, elasticity and intensity prepared by the PLGA of molecular weight between 0.5 ~ 200,000 can meet the demands.
After PLGA meets water (tissue fluid), PLGA molecule precipitation also rearranges film forming according to tissue surface shape, and make because of the participation of hydrone in film forming procedure to form micro-cavernous structure in film, this film has following features:
1, micro-cavernous structure ensure that film has good flexibility;
2, fit like a glove with tissue surface shape, attaching property is good, does not move;
3, selectivity is through water analysis, air and micromolecule nutrient substance, not overslaugh organization healing.
PLGA can auto-degradation, and degradation time is reasonable in design, can tide over scar hyperplasia active phase with organization healing.Gel after film forming is slowly degraded to the micromolecule such as lactic acid monomer, and participation organism metabolism, is finally degraded to carbon dioxide and water excretes, noresidue in vivo.
PLGA is nontoxic, non-stimulated, apyrogeneity, foreign sense, final catabolite is carbon dioxide and water, noresidue in body; U.S. FDA approved is applied.
Main operation completes and thoroughly stops blooding and after debridement, by this product uniform fold in the surgical wound surface needing anti, can close surgical pathway after film forming to be solidified.

Claims (6)

1. a Poly(D,L-lactide-co-glycolide antiblocking liquor, it is characterized in that its in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate=1: (1 ~ 15); Described Poly(D,L-lactide-co-glycolide in mass ratio consist of polylactic acid: hydroxyacetic acid=1: (0.2 ~ 5), the mean molecule quantity of described Poly(D,L-lactide-co-glycolide is 0.5 ~ 200,000.
2. a kind of Poly(D,L-lactide-co-glycolide antiblocking liquor as claimed in claim 1, it is characterized in that described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate is 1: (1 ~ 3.5).
3. a kind of Poly(D,L-lactide-co-glycolide antiblocking liquor as claimed in claim 1, it is characterized in that described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate is 1: (3.5 ~ 7).
4. a kind of Poly(D,L-lactide-co-glycolide antiblocking liquor as claimed in claim 1, it is characterized in that described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate is 1: (7 ~ 11).
5. a kind of Poly(D,L-lactide-co-glycolide antiblocking liquor as claimed in claim 1, it is characterized in that described Poly(D,L-lactide-co-glycolide antiblocking liquor in mass ratio consist of Poly(D,L-lactide-co-glycolide: ethyl acetate is 1: (11 ~ 15).
6., as the preparation method of Poly(D,L-lactide-co-glycolide antiblocking liquor as described in arbitrary in Claims 1 to 5, it is characterized in that its concrete steps are as follows:
Ethyl acetate is added in Poly(D,L-lactide-co-glycolide, after mixing, namely obtain Poly(D,L-lactide-co-glycolide antiblocking liquor.
CN201510249690.9A 2015-05-15 2015-05-15 Anti-adhering liquid of polylactic acid-hydroxyacetic acid copolymer and preparation method thereof Pending CN104873535A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510249690.9A CN104873535A (en) 2015-05-15 2015-05-15 Anti-adhering liquid of polylactic acid-hydroxyacetic acid copolymer and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510249690.9A CN104873535A (en) 2015-05-15 2015-05-15 Anti-adhering liquid of polylactic acid-hydroxyacetic acid copolymer and preparation method thereof

Publications (1)

Publication Number Publication Date
CN104873535A true CN104873535A (en) 2015-09-02

Family

ID=53941391

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510249690.9A Pending CN104873535A (en) 2015-05-15 2015-05-15 Anti-adhering liquid of polylactic acid-hydroxyacetic acid copolymer and preparation method thereof

Country Status (1)

Country Link
CN (1) CN104873535A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109381479A (en) * 2017-08-08 2019-02-26 于晓彤 A kind of surgical operation anti-sticking flush fluid
CN113855850A (en) * 2020-06-30 2021-12-31 孛朗孚(杭州)生物科技有限公司 Dressing composition and preparation method and application thereof
CN113855849A (en) * 2020-06-30 2021-12-31 孛朗孚(杭州)生物科技有限公司 Dressing composition and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397580A (en) * 2011-11-04 2012-04-04 无锡中科光远生物材料有限公司 Anti-adhesion fiber membrane with hemostasis and antibiosis functions and preparation method thereof
CN103110984A (en) * 2013-02-20 2013-05-22 上海典范医疗科技有限公司 Method for preparing hemostatic polylactic acid anti-adhesion film

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397580A (en) * 2011-11-04 2012-04-04 无锡中科光远生物材料有限公司 Anti-adhesion fiber membrane with hemostasis and antibiosis functions and preparation method thereof
CN103110984A (en) * 2013-02-20 2013-05-22 上海典范医疗科技有限公司 Method for preparing hemostatic polylactic acid anti-adhesion film

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
庞秀炳等: "聚乳酸/乙醇酸可吸收医用膜对兔腹腔术后粘连的预防作用研究", 《中国医疗器械杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109381479A (en) * 2017-08-08 2019-02-26 于晓彤 A kind of surgical operation anti-sticking flush fluid
CN113855850A (en) * 2020-06-30 2021-12-31 孛朗孚(杭州)生物科技有限公司 Dressing composition and preparation method and application thereof
CN113855849A (en) * 2020-06-30 2021-12-31 孛朗孚(杭州)生物科技有限公司 Dressing composition and preparation method and application thereof

Similar Documents

Publication Publication Date Title
Laurencin et al. Natural and synthetic biomedical polymers
Kariduraganavar et al. Polymer synthesis and processing
Domb et al. Biodegradable polymers in clinical use and clinical development
AU782265B2 (en) Biodegradable polymer composition
US8163714B2 (en) Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery
CN101623517B (en) Medical anti-sticking membrane and preparation method thereof
JP6063867B2 (en) Disulfide bond cross-linked biocompatible polymer hydrogel and formulation containing the same
EP2821087B1 (en) Anti-adhesion polymer composition capable of supporting growth factor
CN101677957A (en) The polymer formulations that is used for delivery of bioactive agents
JP2008524235A5 (en)
JP2010104791A (en) Delayed gelation composition and method of use
CN101557802B (en) Self solidifying bioerodible barrier implant
KR101871930B1 (en) Thermo-sensitive Anti-adhesion Hydrogel Using Hyaluronic Acid Derivative And Manufacturing Method Thereof
CN106659823B (en) Thermo-responsive is anti-sticking to be used in conjunction composition and application thereof
WO2016114355A1 (en) Composition for preventing adhesion
CN104873535A (en) Anti-adhering liquid of polylactic acid-hydroxyacetic acid copolymer and preparation method thereof
TWI731076B (en) Multiphase gel
KR20120127471A (en) Polymer gel formulation
JP2014528406A (en) Multilayer implant for delivering therapeutic agents
US20140329756A1 (en) Temperature-release catalyst for cross-linking halyuronic acid during injection
KR101799534B1 (en) Composition for preventing tissue adhesion and method for preparing the same
CN103951950B (en) Flexible biological degradable composite material
CA2682291C (en) Device made at least partially of n-acetylchitosan with controlled biodissolution
JP4854299B2 (en) Anti-adhesive material
Narasimhan et al. Revisiting the properties of suture materials: An overview

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150902